Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Public ClinicalTrials.gov record NCT01474109. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Study identification
- NCT ID
- NCT01474109
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Actelion
- Industry
- Enrollment
- 289 participants
Conditions and interventions
Conditions
Interventions
- macitentan 3mg Drug
- macitentan 10mg Drug
- placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2011
- Primary completion
- Oct 31, 2013
- Completion
- Oct 31, 2013
- Last update posted
- Jan 5, 2015
2011 – 2013
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona Arthritis Center | Tucson | Arizona | 85724 | — |
| UCLA Medical School - Rheumatology Division Rehabilitation Center | Los Angeles | California | 90095 | — |
| Arthritis & Rheumatic Disease Specialties | Aventura | Florida | 33180 | — |
| Sarasota Arthritis Research Center | Sarasota | Florida | 34239 | — |
| Ochsner Medical Center | New Orleans | Louisiana | 70121 | — |
| The Johns Hopkins University School of Medicine | Baltimore | Maryland | 21224-6801 | — |
| University of Michigan - Scleroderma Program | Ann Arbor | Michigan | 48109 | — |
| Michigan State University | Grand Rapids | Michigan | 49546 | — |
| University of Medicine & Dentistry of New Jersey, UMDNJ Scleroderma Program | New Brunswick | New Jersey | 08903-0010 | — |
| The Center for Rheumatology | Albany | New York | 12206 | — |
| Shanahan Rheumatology and Immunotherapy, PLLC | Raleigh | North Carolina | 27617-7884 | — |
| The Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Altoona Center for Clinical Research | Duncansville | Pennsylvania | 16635 | — |
| University of Pittsburgh Department of Rheumatology | Pittsburgh | Pennsylvania | 15261 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425-8905 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 62 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01474109, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 5, 2015 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01474109 live on ClinicalTrials.gov.